Drug Pipeline for MASLD: What Can Be Learned from the Successful Story of Resmetirom

Area of Science:

• Hepatology and Metabolic Disorders
• Pharmacology and Drug Development

Background:

• Metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction-associated steatohepatitis (MASH), are increasing global health concerns.
• MASLD is associated with obesity, insulin resistance, and dyslipidemia, often progressing to severe liver damage including cirrhosis and cancer.
• Current therapeutic strategies for MASLD/MASH are limited, necessitating the development of novel pharmacological treatments.

Purpose of the Study:

• To review the therapeutic potential of resmetirom, a selective thyroid hormone receptor beta (THR-β) agonist, for MASLD and MASH.
• To examine the mechanism of action, clinical efficacy, and safety profile of resmetirom based on pivotal study evidence.
• To compare resmetirom with other emerging therapies for MASLD/MASH.

Main Methods:

• Review of evidence from early- and advanced-phase clinical trials, including the MAESTRO program.
• Analysis of resmetirom's impact on hepatic triglyceride accumulation, lipid profiles, and liver fat content.
• Evaluation of resmetirom's effects on noninvasive biomarkers of liver fibrosis and assessment of its safety profile.

Main Results:

• Resmetirom demonstrated significant reductions in hepatic fat content and improvements in lipid profiles in clinical trials.
• Studies showed favorable impacts on noninvasive biomarkers of liver fibrosis.
• Resmetirom was generally well-tolerated, with minimal reported side effects.

Conclusions:

• Resmetirom represents a promising targeted pharmacological intervention for MASLD and MASH, particularly in non-cirrhotic MASH.
• Its selective action on hepatic metabolism offers a potential advantage over less targeted approaches.
• Further long-term studies are required to confirm clinical benefits and support potential regulatory approval for broader MASLD/MASH management.